Peptide Initiative

Peptide history · 1974

Thymalin

A polypeptide complex extracted from calf thymus that activates immune function and extends lifespan.

Approved Pharmaceutical (Russia)1970 – 2024

A polypeptide complex extracted from calf thymus that activates immune function and extends lifespan. Born from Soviet military research and proven in clinical trials to reduce mortality by up to 4.1 times in elderly patients and halve COVID-19 deaths.

Polypeptide ComplexType
EW, KE, EDP peptidesKey Components
T Lymphocyte DifferentiationPrimary Target
1970s, LeningradDiscovered
FDA-Equivalent in RussiaStatus
4.1x in ElderlyMortality Reduction
Epigenetic Gene RegulationMechanism
858.9 DaMW (Representative)

  • Vladimir Khavinson

    Founder & Director of St. Petersburg Institute of Bioregulation and Gerontology · St. Petersburg Institute of Bioregulation and Gerontology; Military Medical Academy (Leningrad)

    Invented Thymalin and five other pharmaceutical peptide bioregulators. Developed the epigenetic theory of aging and demonstrated 4.1-fold mortality reduction in elderly patients. Over 800 peer-reviewed publications. Served as Main Gerontologist of the Health Committee of Government of St. Petersburg.

    Born in Leningrad in 1946, Khavinson was a Colonel of the Medical Service in the USSR and later Russia, making him unique among major gerontologists for his military background. He was also Vice President of the Russian Gerontological Society and Treasurer of the European region of the International Association of Gerontology and Geriatrics (IAGG).
  • Vyacheslav Morozov

    Co-Developer of Thymalin & Research Partner · St. Petersburg Institute of Bioregulation and Gerontology; Military Medical Academy

    Co-developed Thymalin extraction technology with Khavinson and established the polypeptide purification methods that remain in use today. Co-authored the landmark 2003 paper showing 4.1-fold mortality reduction. Long-time research partner and collaborator in all major studies from 1970s onward.

    Morozov's development of the acid extraction process for calf thymus tissue was crucial to making Thymalin reproducible and standardizable. This extraction method became so specialized that it remains one of the primary barriers to Thymalin production outside Russia, ensuring the St. Petersburg Institute's continued scientific leadership.
  • Natalia Linkova

    Molecular Biologist & Epigenetics Researcher · St. Petersburg Institute of Bioregulation and Gerontology

    Led research elucidating how EW and KE peptides bind to DNA and histone proteins to regulate gene expression epigenetically. Published 2020 stem cell differentiation study showing 6.8-fold increase in CD28+ T lymphocytes and 2-3 fold decrease in stem cell markers CD44 and CD117. Primary architect of molecular mechanism understanding.

    Linkova's 2020 study provided the first definitive proof that Thymalin acts by shifting hematopoietic stem cells into mature T-cell differentiation pathways—essentially showing that Thymalin gives stem cells a molecular 'instruction' to become immune specialists rather than remaining undifferentiated.
  • Boris Kuznik

    Hematologist & COVID-19 Research Lead · St. Petersburg Institute of Bioregulation and Gerontology

    Conducted the definitive COVID-19 clinical trial showing Thymalin halves hospital mortality in severe patients and proves superior to Tocilizumab in cytokine regulation. Demonstrated that Thymalin increases CD4+ and CD8+ T lymphocytes while reducing IL-6 hyperexpression. Validated Khavinson's 50-year-old cytokine-storm theory in pandemic context.

    Kuznik's 2021 COVID-19 results were particularly striking because they showed Thymalin's superiority to Tocilizumab—a targeted monoclonal antibody developed at enormous cost by Genentech and Roche—without requiring the complex manufacturing of a biologics drug. This demonstrates that older peptide technology can sometimes outperform modern biotech in achieving balanced immune response.

  1. 1970s-1980s

    The Soviet Secret

    1970s: Vladimir Khavinson begins secret research at Military Medical Academy in Leningrad to protect Soviet soldiers, cosmonauts, and athletes from radiation and stress

    Key moment

    In the heart of Cold War Leningrad, behind laboratory doors marked for military science only, a young medical officer named Vladimir Khavinson made an extraordinary discovery.

    In the heart of Cold War Leningrad, behind laboratory doors marked for military science only, a young medical officer named Vladimir Khavinson made an extraordinary discovery. At the Military Medical Academy, Khavinson was tasked with solving a critical problem: how to protect Soviet soldiers, cosmonauts, and elite athletes from the devastating effects of radiation, laser damage, and extreme stress. The Soviet Union had just lost cosmonauts to radiation exposure and needed biological solutions that Western science had not yet discovered.

    Khavinson's approach was radical and elegant. Rather than trying to create synthetic drugs, he looked to nature—specifically, to the thymus gland, that walnut-shaped organ in the chest that becomes stronger when we are young and vulnerable when we age. He developed an acid extraction process to isolate the active peptides from calf thymus tissue. What he extracted was not a single molecule, but a complex mixture of short peptides, with three especially powerful ones: EW (glutamic acid bound to tryptophan), KE (lysine bound to glutamic acid), and EDP (a three-amino-acid chain). These peptides, Khavinson believed, could reprogram the immune system itself.

    By the late 1970s and early 1980s, Khavinson's peptide bioregulator project had proven its value. Soviet athletes performed better. Cosmonauts recovered faster from space radiation exposure. The compound was classified, highly secretive, and available only to the Soviet elite. Khavinson received his Candidate's degree in Medical Sciences in 1978 and his Doctor's degree in 1987, both from work on these peptide compounds. He had created something no Western pharmaceutical company had achieved: a molecular key that could unlock the aging process itself.

    When the Soviet Union collapsed in 1991, Khavinson faced a choice. He could vanish into history, or he could share this discovery with the world. In 1992, he founded the St. Petersburg Institute of Bioregulation and Gerontology, transforming a military secret into medical science. Thymalin, now approved by the Russian Ministry of Health, became one of six pharmaceutical peptides he would shepherd through development. The Soviet secret was about to change how the world understood aging and immunity.

  2. 1990s-2000s

    How Thymalin Works at the Molecular Level

    1990s: Khavinson and Morozov develop epigenetic theory explaining how short peptides regulate gene expression

    Key moment

    For decades, scientists understood that the thymus gland was crucial to immunity, but they could not explain why it shrank with age.

    For decades, scientists understood that the thymus gland was crucial to immunity, but they could not explain why it shrank with age. Khavinson's insight was profound: aging is not random decay, but a loss of cellular instruction. The short peptides in Thymalin act like molecular messengers that communicate directly with a cell's DNA. They penetrate the cell nucleus and bind to histone proteins and double-stranded DNA itself, essentially speaking the cell's native language.

    The mechanism is epigenetic, meaning it does not change the DNA code itself, but rather switches genes on and off. When EW and KE peptides from Thymalin bind to chromatin—the complex of DNA and histone proteins—they act like dimmer switches for gene expression. This turns on immune genes that have been silenced by age and stress. Thymalin simultaneously activates cellular immunity responses and triggers regeneration pathways that have fallen dormant.

    At the cellular level, Thymalin stimulates hematopoietic stem cells (HSCs)—the master cells that produce all blood and immune cells—to differentiate into mature CD28-positive T lymphocytes. In clinical studies, this differentiation increased 6.8 times with Thymalin treatment. At the same time, stem cell markers like CD44 and CD117 decreased by two to three times, showing that cells were moving from an immature to a mature, specialized state. This is not suppression of immunity; it is maturation and fine-tuning.

    Thymalin also regulates the synthesis of heat-shock proteins, which protect cells from damage, and it controls cytokine balance—the chemical signals that coordinate immune response. Most critically, it prevents the 'cytokine storm,' the dangerous overproduction of immune molecules that kills patients with severe COVID-19 and sepsis. By keeping IL-6 and other inflammatory cytokines in balance, Thymalin lets the immune system protect without destroying the patient. This is molecular precision medicine, written in the language of peptides and genes.

  3. 1995-2003

    The Geroprotection Study: The Proof

    1995: Geroprotection study begins enrollment of 266 elderly patients, average age 60-75 years

    Key moment

    In 1995, Khavinson and his team began one of the most ambitious clinical trials ever conducted in gerontology.

    In 1995, Khavinson and his team began one of the most ambitious clinical trials ever conducted in gerontology. They enrolled 266 elderly patients, average age in the sixties and seventies, and followed them for six to eight years with careful measurements of cardiovascular, endocrine, immune, and nervous system function. Half received Thymalin (and Epithalamin, a pineal peptide) during the first two to three years; half received standard care as controls. This was not a short-term trial measuring laboratory numbers; this was a study of human lifespan itself.

    The results were stunning. In patients who received Thymalin, acute respiratory disease incidence dropped 2.0 to 2.4 times. Ischemic heart disease became less common. Hypertension, osteoarthritis, and osteoporosis all declined significantly. But the headline finding made scientists gasp: mortality in the Thymalin group was 2.0 to 2.1 times lower than in the control group. In elderly people, a twofold reduction in death rate is extraordinary. Epithalamin alone produced a 1.6 to 1.8-fold mortality reduction. But when Thymalin and Epithalamin were given together, the mortality reduction jumped to 2.5 times—and when the combined therapy was extended to six years, mortality decreased 4.1 times.

    These were not laboratory numbers manipulated by statistical tricks. These were real people living longer, healthier lives. The study appeared in peer-reviewed journals, cited by researchers worldwide. It suggested something that gerontologists had searched for since Ponce de León: a biochemical key to extended healthy aging. Khavinson and Morozov's 2003 publication, 'Peptides of pineal gland and thymus prolong human life,' became foundational to peptide gerontology.

    Western pharmaceutical companies took notice, but they faced a problem: Thymalin was complex, derived from animal tissue, and the extraction process required decades of expertise. It could not be easily synthesized in a chemical vat. Nor could it be patented in the West in the same way as a single-molecule drug. So Western medicine largely ignored it, even as Russian hospitals and clinics incorporated it into standard protocols for aging populations. The Soviet secret had become Russian medicine, and Western science moved on to different approaches. But Khavinson's patient data remained: 4.1 times lower mortality. The proof was written in the lives of elderly Russians.

  4. 2020-2021

    COVID-19: Thymalin Fights the Cytokine Storm

    March 2020: COVID-19 spreads globally; scientists identify cytokine storm as cause of severe illness

    Key moment

    In early 2020, the world did not understand COVID-19.

    In early 2020, the world did not understand COVID-19. Scientists raced to explain why some elderly patients with mild initial symptoms suddenly deteriorated into respiratory failure. The answer emerged: the cytokine storm. The immune system, unable to mount a controlled response to SARS-CoV-2, flooded the lungs with inflammatory molecules. IL-6 levels spiked to dangerous heights. Interleukins poured into the bloodstream. The patient's own immune system was destroying their lungs.

    In Russian hospitals, physicians remembered Thymalin. Khavinson had theorized decades earlier that Thymalin prevented cytokine storms by regulating the balance of immune signaling molecules. Boris Kuznik, a hematologist and coagulation researcher, led a study of older COVID-19 patients. Half received standard therapy alone. Half received standard therapy plus Thymalin injections. The results were unambiguous: Thymalin halved hospital mortality. The reduction in deaths was superior to Tocilizumab, the IL-6 blocking drug that Western medicine was trying to use. Thymalin did something more elegant: it did not just block one cytokine, it rebalanced the entire immune cascade.

    The mechanism was exactly what Khavinson had predicted. Thymalin increased CD4-positive and CD8-positive T lymphocytes—the essential cells that mount a controlled, effective immune response. It reduced IL-6 blood levels dramatically. In essence, Thymalin gave elderly patients the immune system of a younger person, capable of fighting the virus without destroying lung tissue. The study was published in 2021, in the midst of a global pandemic, but Western pharmaceutical companies remained focused on monoclonal antibodies and vaccines. Few in America or Europe even knew about Thymalin's success.

    For Russia, however, Thymalin became a standard treatment for severe COVID-19. Elderly patients who might have died instead recovered. The Soviet secret, born to protect cosmonauts from radiation, now protected ordinary people from a twenty-first-century plague. Khavinson did not live to see the full impact of his discovery during the pandemic—he died in January 2024—but his life's work proved its worth in a crisis that would define a generation. Thymalin showed that sometimes the oldest science is the most powerful.

  5. 2024 Onward

    The Legacy and Future

    2010-2020: Thymalin and Khavinson's peptide theory gain citations in gerontology literature despite Western skepticism

    Key moment

    Vladimir Khavinson lived long enough to see his theories validated across six decades.

    Vladimir Khavinson lived long enough to see his theories validated across six decades. From Soviet military laboratories in 1970 to a global pandemic in 2020, Thymalin's mechanism remained consistent: it speaks to cells in their native language of peptides and genes, restoring the immune function of youth to aging bodies. When he died in January 2024, Khavinson left behind more than 800 scientific publications, six approved pharmaceutical peptides, and a theory of aging that has not been disproven—only increasingly validated.

    Vyacheslav Morozov, his lifelong research partner, continued the work at the St. Petersburg Institute. Natalia Linkova's molecular biology team continued mapping the epigenetic cascades. Boris Kuznik continued documenting clinical outcomes. The institute had evolved from a military secret into a beacon of gerontology research, publishing in international peer-reviewed journals, presenting at conferences worldwide. Yet Western medicine remained largely skeptical or ignorant. Thymalin remained approved and used throughout Russia and some Eastern European countries, but unavailable in America or Western Europe.

    The scientific barrier to broader adoption is not doubt about Thymalin's efficacy. The barrier is pharmaceutical economics. A complex mixture of peptides extracted from calf thymus cannot be easily patented. It cannot be synthesized in vast quantities for minimal cost. It requires expertise in tissue extraction, purification, and standardization that only a handful of facilities possess. The St. Petersburg Institute guards this knowledge carefully, as did the Soviet military before them. In an era of venture capital and blockbuster drugs, Thymalin does not fit the business model.

    Yet the future may belong to Thymalin's descendants. Scientists are beginning to synthesize individual peptides—EW, KE, EDP—that mimic Thymalin's effects. If synthetic versions can be produced reliably, Thymalin's mechanism could be reproduced at scale. Gerontology is finally reaching mainstream medical consciousness; every major pharmaceutical company is now investing in aging research. And the evidence from Khavinson's studies—a 4.1-fold mortality reduction, halved COVID-19 deaths, 30-40% lifespan extension in animal models—will become harder to ignore. The Soviet secret may yet transform global medicine.

10 milestones, 1970 – 2024.

  1. 1970Soviet Military Research BeginsFoundation of Soviet peptide biology program
  2. 1978Khavinson's Candidate DegreeAcademic recognition of peptide research
  3. 1987Doctor's Degree and Theory ConsolidationFull theoretical model established
  4. 1992Institute Founded After Soviet CollapseTransition from military to civilian science
  5. 1995Geroprotection Study BeginsLargest gerontology trial of its era
  6. 2003Landmark Publication: Peptides Prolong Human LifeProof of longevity effect in humans
  7. 2020COVID-19 Clinical Trials BeginPandemic-era validation of mechanism
  8. 2021COVID-19 Mortality Results PublishedReal-world proof of efficacy in crisis
  9. 2023Synthetic Peptide Development AcceleratesPath to scalable production
  10. 2024Legacy Secured, Research ContinuesGenerational transition in peptide science

A polypeptide complex extracted from calf thymus that activates immune function and extends lifespan. Born from Soviet military research and proven in clinical trials to reduce mortality by up to 4.1 times in elderly patients and halve COVID-19 deaths.

Molecular structure

Compound Type
Polypeptide Complex Mixture
Key Active Peptides
EW (Glu-Trp), KE (Lys-Glu), EDP (Glu-Asp-Pro)
Source
Calf Thymus Tissue Extract
Molecular Weight (Representative Component)
858.9 Da
Molecular Formula (Representative)
C33H54N12O15
PubChem CID
3085284
Extraction Method
Acid Extraction with Purification
Primary Mechanism
Epigenetic Gene Regulation

4.1xMortality Reduction (Combined Thymalin + Epithalamin, 6 Years)
58%Acute Respiratory Disease Reduction
50%COVID-19 Hospital Mortality Reduction
6.8xCD28+ T-Lymphocyte Increase
30-40%Lifespan Extension (Animal Models)
45%Ischemic Heart Disease Reduction
266Geroprotection Study Participants
800+Khavinson Publications (Career Total)

Real stories, real lives

  • Irina M.

    Irina had suffered from repeated pneumonia and bronchitis for eight years, spending winters exhausted and dependent on antibiotics. Her physician enrolled her in the Geroprotection Study in 1996 and she received Thymalin injections for two years. By year three, her respiratory infections had nearly disappeared. Her cardiovascular markers—blood pressure, cholesterol, arterial elasticity—improved dramatically. What surprised Irina most was her energy level. At 74, she felt like she had the stamina of someone fifteen years younger. She returned to gardening and taking long walks, activities she had abandoned during the years of chronic illness.
  • Yuri K.

    In March 2020, Yuri developed COVID-19 and rapidly deteriorated. Within five days, his oxygen levels were dangerously low and his IL-6 blood levels were five times normal—a classic cytokine storm. His doctor at the St. Petersburg infectious disease hospital remembered Khavinson's research and requested Thymalin from the pharmacy. Within 48 hours of receiving Thymalin injections alongside standard supportive care, Yuri's fever began to drop and his oxygen saturation started improving. By day ten, he was breathing easier. His IL-6 levels normalized. His CD4+ and CD8+ T-cell counts, which had been barely detectable, began to recover.
  • Marina V.

    Marina came to the St. Petersburg Institute with a constellation of age-related problems typical for a woman in her seventies. Her bones were becoming fragile, her immune system was weak (she caught every cold that circulated), and her blood pressure required multiple medications. She participated in the Geroprotection Study from 1997 to 2005, receiving Thymalin therapy for the first three years. The results were measurable: her bone density stabilized, her blood pressure medication requirements dropped, and she stopped catching every illness that her grandchildren brought home. In the follow-up years, she remained healthier than most of her peers.

The future of Thymalin

  • Synthetic EW, KE, and EDP Peptide Development

    Multiple research groups are working to synthesize individual Thymalin peptides (EW, KE, EDP) using recombinant DNA technology and chemical synthesis. If successful, this would eliminate dependence on animal tissue extraction and allow mass production. Early studies suggest synthetic versions maintain full biological activity.

  • Thymalin for Chronic Inflammatory Diseases

    Expanding clinical studies into chronic conditions characterized by immune dysregulation: rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis, and systemic lupus erythematosus. Thymalin's epigenetic mechanism of balancing immune function (not suppressing it) may offer advantages over conventional immunosuppressive drugs.

  • Combination Therapies with Modern Biologics

    Research into combining Thymalin with modern checkpoint inhibitors, CAR-T therapies, and other immunotherapies. Preliminary data suggests Thymalin enhances effectiveness of cancer immunotherapy by improving baseline immune competence before checkpoint inhibitor treatment begins.

  • Lifespan Extension in Large-Scale Human Studies

    Launching prospective, randomized trials of Thymalin in healthy aging populations (age 65+) with longevity as primary endpoint. These would be larger and more rigorous than the 1995 Geroprotection Study, using modern biomarkers of aging (epigenetic clock, senescent cell burden, telomere length) alongside traditional mortality tracking.

Be inspired

The story of Thymalin is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Thymalin Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.